Tags

Type your tag names separated by a space and hit enter

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015.
Emerg Infect Dis. 2017 07; 23(7):1079-1084.EI

Abstract

We investigated the kinetics of the Middle East respiratory syndrome coronavirus (MERS-CoV) neutralizing and spike protein antibody titers over the course of 1 year in 11 patients who were confirmed by reverse transcription PCR to have been infected during the outbreak in South Korea in 2015. Robust antibody responses were detected in all survivors who had severe disease; responses remained detectable, albeit with some waning, for <1 year. The duration of viral RNA detection (but not viral load) in sputum significantly correlated with the antibody response magnitude. The MERS S1 ELISA antibody titers correlated well with the neutralizing antibody response. Antibody titers in 4 of 6 patients who had mild illness were undetectable even though most had evidence of pneumonia. This finding implies that MERS-CoV seroepidemiologic studies markedly underestimate the extent of mild and asymptomatic infection. Obtaining convalescent-phase plasma with high antibody titers to treat MERS will be challenging.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Historical Article
Journal Article

Language

eng

PubMed ID

28585916

Citation

Choe, Pyoeng Gyun, et al. "MERS-CoV Antibody Responses 1 Year After Symptom Onset, South Korea, 2015." Emerging Infectious Diseases, vol. 23, no. 7, 2017, pp. 1079-1084.
Choe PG, Perera RAPM, Park WB, et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg Infect Dis. 2017;23(7):1079-1084.
Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K. H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N. J., Lau, E. H. Y., Poon, L. L. M., Peiris, M., & Oh, M. D. (2017). MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerging Infectious Diseases, 23(7), 1079-1084. https://doi.org/10.3201/eid2307.170310
Choe PG, et al. MERS-CoV Antibody Responses 1 Year After Symptom Onset, South Korea, 2015. Emerg Infect Dis. 2017;23(7):1079-1084. PubMed PMID: 28585916.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. AU - Choe,Pyoeng Gyun, AU - Perera,R A P M, AU - Park,Wan Beom, AU - Song,Kyoung-Ho, AU - Bang,Ji Hwan, AU - Kim,Eu Suk, AU - Kim,Hong Bin, AU - Ko,Long Wei Ronald, AU - Park,Sang Won, AU - Kim,Nam-Joong, AU - Lau,Eric H Y, AU - Poon,Leo L M, AU - Peiris,Malik, AU - Oh,Myoung-Don, Y1 - 2017/07/15/ PY - 2017/6/7/pubmed PY - 2018/3/27/medline PY - 2017/6/7/entrez KW - China KW - MERS KW - MERS-CoV KW - Middle East respiratory syndrome coronavirus KW - South Korea KW - antibody KW - coronavirus KW - human KW - kinetics KW - neutralization KW - serology KW - viruses KW - zoonoses SP - 1079 EP - 1084 JF - Emerging infectious diseases JO - Emerg Infect Dis VL - 23 IS - 7 N2 - We investigated the kinetics of the Middle East respiratory syndrome coronavirus (MERS-CoV) neutralizing and spike protein antibody titers over the course of 1 year in 11 patients who were confirmed by reverse transcription PCR to have been infected during the outbreak in South Korea in 2015. Robust antibody responses were detected in all survivors who had severe disease; responses remained detectable, albeit with some waning, for <1 year. The duration of viral RNA detection (but not viral load) in sputum significantly correlated with the antibody response magnitude. The MERS S1 ELISA antibody titers correlated well with the neutralizing antibody response. Antibody titers in 4 of 6 patients who had mild illness were undetectable even though most had evidence of pneumonia. This finding implies that MERS-CoV seroepidemiologic studies markedly underestimate the extent of mild and asymptomatic infection. Obtaining convalescent-phase plasma with high antibody titers to treat MERS will be challenging. SN - 1080-6059 UR - https://www.unboundmedicine.com/medline/citation/28585916/MERS_CoV_Antibody_Responses_1_Year_after_Symptom_Onset_South_Korea_2015_ L2 - https://doi.org/10.3201/eid2307.170310 DB - PRIME DP - Unbound Medicine ER -